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Objectives: Scale-up of HIV services in sub-Saharan Africa has rapidly increased, necessitating evaluation
of medication safety in these settings. Drug–drug interactions (DDIs) involving antiretrovirals (ARVs) in
sub-Saharan Africa are poorly characterized. We evaluated the prevalence and type of ARV DDIs in Ugandan
outpatients and identified the patients most at risk.
Methods: A total of 2000 consecutive patients receiving ARVs at the Infectious Diseases Institute, Kampala were
studied. The most recent prescription for each patient was screened for clinically significant DDIs using www.
hiv-druginteractions.org. Univariable and multivariable logistic regression were used to identify risk factors for
DDIs. A screening tool was developed using significant risk factors and tested in a further 500 patients.
Results: Clinically significant DDIs were observed in 374 (18.7%) patients, with a total of 514 DDIs observed. Only
0.2% of DDIs involved a contraindicated combination. Comedications commonly associated with DDIs were anti-
biotics (4.8% of 2000 patients), anthelmintics (2.2%) and antifungals (3.5%). Patient age, gender, CD4 count and
weight did not affect risk of DDIs. In multivariable analysis, the patient factors that independently increased risk
of DDIs were two or more comedications (P,0.0001), a PI-containing ARV regimen (P,0.0001), use of an anti-
infective (P,0.0001) and WHO clinical stage 3–4 (P¼0.04). A scoring system based on having at least two of
these risk factors identified between 75% and 90% of DDIs in a validation cohort.
Conclusions: Significant ARV DDIs occur at similar rates in resource-limited settings and developed countries;
however, the comedications frequently causing DDIs differ. Development of tools that are relevant to particular
settings should be a priority to assist with prevention and management of DDIs.
Introduction
Successful scale-up of HIV services in countries such as Uganda
may have contributed to an overall increase in functional health
facilities, a rise in patient engagement and retention in care.1 As
more patients access medical care, including ART, evaluating medi-
cation safety is increasingly important in these settings.2 Current
ART is complex due to lifelong treatment comprising multidrug
regimens with significant propensity for drug–drug interactions
(DDIs), which may result in raising or lowering the concentration
of coprescribed drugs or antiretrovirals (ARVs). Elevated drug con-
centrations may be associated with drug toxicity and lower concen-
trations may be associated with therapeutic failure. Subtherapeutic
drug concentrations are of particular concern when treating HIV,
due to the possible emergence of drug-resistant strains, which
can compromise the utility of ARVs and reduce future treatment
options on an individual patient or population basis. Studies from
Europe, the USA and South America have reported a prevalence
of clinically significant DDIs of 14%–58%,3 – 8 suggesting DDIs
involving ARVs are common, frequently unavoidable but manage-
able in the majority of cases. However, physician recognition of ARV
DDIs has been reported to be low in a UK study.3 Few data are avail-
able in low-resource settings; the prevalence of DDIs ranged from
14.8%–33.5% in three studies undertaken in Nigeria, Kenya and
South Africa.9 –11
Resource-limited settings in sub-Saharan Africa are likely to
face specific risk factors for DDIs. Here, a public health approach
is deployed to maximize health gains for the population who
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require treatment (with most individuals managed using a com-
bination of clinical monitoring and symptom-driven laboratory
monitoring), in contrast to individualized therapy in developed
countries. Medication recording in clinical notes may be incom-
plete, as reported in UK studies.7,12 This may pose a risk in
African settings, where ‘vertical’ (unintegrated) programmes for
HIV, TB, malaria and other conditions exist. Detection of subther-
apeutic ARV levels is complex in the absence of therapeutic drug
monitoring as there may be a delay between the index prescribing
event and the emergence of clinical or virological failure. In the
developed world, management of DDIs may involve substitution
of a medication or adjustment of doses. Laboratory monitoring is
routinely utilized in such situations, but is largely unavailable in
resource-limited settings. It is therefore vital that the common
interactions of clinical importance in such settings are recognized
and detected, in order to prevent patient harm.
We studied the prevalence and type of DDIs involving ARVs in a
large Ugandan outpatient ARV programme in order to identify fac-
tors associated with risk of having DDIs and to develop a simple
screening tool to identify patients most at risk of having clinically
significant DDIs in this setting.
Patients and methods
Setting
The Infectious Diseases Institute (IDI) in Kampala, Uganda, is the national
referral centre for HIV treatment and, at the time of the study, was provid-
ing care for .9000 patients, of whom 6832 were taking WHO standard
ARV regimens during May 2012. Unusually for sub-Saharan Africa, patient
records and prescribing are via an electronic system, the Integrated Care
Enterprise Application (ICEA), which integrates electronic health records
with electronic prescribing and dispensing, and pathology and radiology
reporting.
Ethical considerations
This is a retrospective study on a large dataset, involving no intervention or
patient contact. Local confidentiality and data protection agreements
were adhered to throughout the study. The protocol for the retrospective
use of data routinely collected at IDI was reviewed and approved by the
Makerere University Faculty of Medicine Research and Ethics Committee
(approval number: 120-2009) and the Uganda National Council for
Science and Technology (approval number: HS 683). According to the
protocol procedures, patients do not provide verbal or written consent,
but all their information is analysed after stripping it of unique personal
identifiers. Linked anonymized data were subsequently used by the clinical
service team to trace all patients with contraindicated drug combinations.
Data collection
A sample of 2000 consecutive patients taking current ARVs and accessing
care at IDI was selected from the clinic database. Exploratory analysis at
the halfway point (1000 patients)13 was equivalent to analysis of the 2000
patient sample. The final analysis was therefore concluded at 2000
patients. This sample represents a third of the adult clinic population
who were receiving ART at the time of the study. Patient demographics
and current medication were recorded in an anonymized database. As
patients were not approached to give a full medication history, only med-
icines prescribed from IDI were recorded.
The most recent prescription for each patient was screened for DDIs
using www.hiv-druginteractions.org. This is a comprehensive database
containing .11000 HIV DDIs, which is widely utilized throughout Europe
and since 2012 has included all drugs from the WHO Model List of Essential
Medicines. The clinical significance of DDIs was assessed and corroborated
by three of the authors (K. S., R. H. and S. K.) using a previously developed
technique evaluating the likelihood of interaction, the therapeutic index of
the affected drug(s) and the severity of the potential adverse effect.3,6 A
quality-of-evidence rating system has been developed and applied to all
interactions in the database, in order to aid clinical decision making.
Potential DDIs excluded from the analysis were those between the
ARV regimen such as tenofovir and lopinavir and between ARVs and
co-trimoxazole. Such combinations are widely used in all settings, with
low likelihood of adverse effects of clinical significance. Co-trimoxazole
was, however, included as a comedication in the analysis. Interactions
between ARVs that were considered to be clinically relevant, e.g. between
efavirenz and lopinavir/ritonavir, were included. Fixed-dose combinations,
e.g. artemether/lumefantrine-containing antimalarials, were considered
in the analysis as one comedication.
Statistical analyses
Relationships between patient characteristics and DDI risk were evaluated.
In descriptive analysis, a t-test was used for means of continuous variables
(Mann–Whitney U-test for non-normally distributed variables: CD4 count)
and a x2 test was used for categorical variables. The ‘cut-offs’ of interest
for continuous variables such as number of comedications were deter-
mined visually. Univariable analysis was used to determine the patient
factors and medication that conferred higher risk of DDIs. Multivariable
logistic regression was used to determine whether the following independ-
ent variables increased patient risk of DDIs involving ARVs: age, gender,
CD4 count, patient weight, WHO clinical stage, number of comedications,
type of comedications and ARV regimen. Forward stepwise selection was
used to fit the model.
A risk factor scoring system was developed using cross-tabulation of
the independent variables found to confer higher risk of DDIs. To use this
system, one ‘point’ was assigned for each risk factor possessed by the
patient and summed together to give a score. Sensitivity and specificity
analysis (ROC curve) was undertaken in a test set of 500 consecutive
patients from the same clinic cohort, which were not included in the
main dataset [prevalence of DDIs: 97 (19.4%); contraindicated combina-
tions: 2 (0.4%)]. In order to identify the most efficient methods to use in
this low-resource setting, scoring system models using different combina-
tions of significant risk factors were compared for more favourable sensi-
tivity and specificity and ease of use.
Analyses were carried out using the SPSS statistical package (v.21; IBM,
NY, USA) and STATA (v.13; STATA, TX, USA).
Results
Patient characteristics
Patient characteristics are shown in Table 1. Patients were predom-
inantly female (65.2%) and the average age was 40.4 years. The
median CD4 count was 391 cells/mm3, with 266 (13.3%) patients
taking a second-line (PI-containing) ARV regimen. Almost all
(99.7%) patients were taking one or more comedication alongside
their ARV regimen, with a mean of 1.9 comedications per patient
recorded.
Prevalence and type of drug interactions
A total of 374 (18.7%) patients had one or more clinically signifi-
cant DDI, with 514 clinically significant interactions identified in
total. Comedication use and prevalence of DDIs with each class
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of comedication is shown in Figure S1 (available as Supplementary
data at JAC Online). Comedications commonly associated with
potential DDIs were antibiotics [103 (20.0%) of 514 interactions,
P,0.0001], antifungals [87 (16.9%), P,0.0001] and anthelmin-
tics [81 (15.8%), P,0.0001]. These affected 95 (4.8%), 70 (3.5%)
and 43 (2.2%) patients, respectively. Antimalarial, steroid and
sedative/anxiolytic use was also significantly associated with
DDIs (P,0.0001); however, patient numbers were low in this
cohort. Contraindicated drug combinations were observed in
four patients (0.2%), all involving nevirapine and ketoconazole.
The observed interactions resulted from the following mechan-
isms: modulation of/competition for metabolic pathways, 359
(69.8%); modulation of/competition for renal elimination of
unchanged drug, 40 (7.8%); and overlapping toxicity, 115 (22.4%).
Risk factor analysis
Table 1 shows the prevalence of drug interactions by patient char-
acteristic. From this descriptive analysis, the cut-offs of at least
two comedications and WHO stage 3–4 were considered rele-
vant. The final multivariable logistic regression model was fitted
by forward stepwise selection and included the use of two or
more comedications, a PI-containing regimen, use of an anti-
infective (antibiotic, antifungal, antimalarial or anthelmintic)
and WHO clinical stage 3–4 (Table 2). These four factors inde-
pendently increased the risk of DDIs.
A risk factor scoring tool was developed incorporating the four
patient factors that were found in descriptive analysis and logistic
regression to significantly increase risk of DDIs. A risk score value
of 2 (i.e. two or more risk factors out of four) was selected as the
cut-off value for screening, based on ROC curve sensitivity and
specificity. A model based on four risk factors was sensitive; how-
ever, specificity was low, requiring the screening of 52.8% of the
cohort to detect 89.7% of the patients with DDIs. This was then
compared with risk score models using combinations of only
three of these factors (Figure 1).
The overall ability of the risk score models to differentiate those
with DDIs from those without ranged from 0.69–0.82 (AUC; see
Figure 1 and Table 3).
Table 3 shows the number and proportion of patients from the
500 patient test dataset that would have been screened using
each model and the number of patients with DDIs and total
Table 1. Prevalence of drug interactions for different patient characteristics
Patient factor All At least one DDI No DDIs Pa
All 2000 374 (18.7%) 1626 (81.3%) —
Age (years), mean (SD) 40.4 (9.05) 40.2 (8.54) 40.4 (9.16) 0.742
Gender female: 1305 (65.2%) 230 (17.6%) 1075 (82.4%) 0.091
male: 695 (34.8%) 144 (20.7%) 551 (79.3%)
Weight (kg), mean (SD) 62.0 (11.48) 61.1 (10.83) 62.2 (11.61) 0.080
CD4 count (cells/mm3), median (range) 391 (4–2603) 369 (4–1666) 397 (5–2603) 0.066
Second-line (PI-containing) regimen 266 (13.3%) 82 (30.8%) 184 (69.2%) ,0.0001
Comedications ,0.0001
0 6 (0.3%) 2 (33.3%)b 4 (66.7%)
1 897 (44.9%) 34 (3.8%) 863 (96.2%)
2 406 (20.3%) 94 (23.2%) 312 (76.8%)
3 663 (33.2%) 231 (34.8%) 432 (65.2%)
≥4 28 (1.4%) 13 (46.4%) 15 (53.6%)
WHO stage ,0.0001
1 89/1997 (4.5%) 9 (10.1%) 80 (89.9%)
2 483/1997 (24.2%) 73 (15.1%) 410 (84.9%)
3 763/1997 (38.2%) 131 (17.2%) 632 (82.8%)
4 662/1997 (33.1%) 161 (24.3%) 501 (75.7%)
at-test/Mann–Whitney U-test used for means of continuous variables and x2 test used for categorical variables.
bInteractions between ARVs only.
Table 2. Logistic regression analysis of patient factors contributing to risk
of DDIs
Multivariable logistic regression analysisa
variable OR (95% CI) P
At least two comedications 3.4 (2.3–5.1) ,0.0001
Second-line (PI-containing) regimen 2.8 (1.9–4.1) ,0.0001
WHO stage 3–4 1.4 (1.0–1.9) 0.04
Anti-infective 11.5 (8.4–15.7) ,0.0001
aVariables removed by forward stepwise regression: weight, CD4 count
and gender.
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number of DDIs detected, if the tool was used to prioritize high-
risk patients for DDI screening.
Discussion
Patients in this African outpatient setting were found to take a
range of prescribed comedications. One or more clinically signifi-
cant DDI affected 18.7% of patients, although contraindicated
combinations were found to be relatively rare. The comedications
most commonly associated with ARV DDIs in this cohort were
anti-infectives. Pharmacokinetic mechanisms involving drug
metabolism accounted for the majority of interactions. The
patients at greatest risk of DDIs were those taking two or more
comedications, taking a PI-containing regimen, taking an anti-
infective (antibiotic, antifungal, anthelmintic or antimalarial) or
WHO clinical stage 3 –4. By prioritizing patients with two or
more of these risk factors for DDI screening, up to 90% of the
patients with DDIs would be identified via screening of ,50% of
the cohort. The available resources would determine the choice of
risk score model, depending on the feasibility of prioritizing28%
of patients for screening to detect 75% of patients with DDIs
(Model 2) or prioritizing 50% of patients to detect almost 90%
of DDIs (Model 1). The method used would also depend on the
simplicity of the scoring system in the clinical context, e.g.
whether the healthcare worker screening patients has reliable
information on current medication and/or WHO clinical stage.
WHO stage may represent a simple measure that could be iden-
tified by a trained healthcare worker or lay person, in order to flag
up high-risk patients for DDI screening (Model 3). In this setting, it
may be possible that anti-infectives or other comedications are
supplied to patients from outside the clinic and these medicines
may not be recorded in clinical notes. If high-risk patients (WHO
stage 3–4, PI regimens and/or at least two comedications) are
prioritized, they can undergo DDI screening, which includes a
full medication history.
Potential DDIs involving ARVs occur at similar rates in resource-
limited settings and developed countries. Drug combinations that
most frequently cause DDIs, however, differ between settings, e.g.
CNS and cardiovascular drugs in the UK3,7 and anti-infectives in
Kenya10 and Uganda. There are some differences in risk factors,
e.g. age confers a higher risk of DDIs in European studies,6
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Figure 1. ROC curve analysis showing sensitivity and specificity of the
screening tool models for detecting patients with DDIs. The point for
each model which relates to two risk factors, the chosen cut-off, is
indicated.
Table 3. Performance of screening tool models for detecting patients with DDIs using combinations of risk factors
Risk score:
Screen patients with
two or more of the
following risk factors ROC AUC (95% CI) Sensitivity Specificity
Patients
screened (%)
Patients
with DDIs
detected (%)
Number of
DDIs detected
(% of DDIs in
cohort)
Contraindicated
combinations detected
(test sample, 2/500; main
sample, 4/2000)
Model 1 0.80 (0.76–0.83) 89.7% 56.1% 264 (52.8) 87 (89.7) 133 (91.1) T: 2
WHO stage 3–4 M: 4
anti-infective
PI regimen
at least two
comedications
Model 2 0.82 (0.79–0.86) 74.2% 82.9% 141 (28.5) 72 (74.2) 109 (74.7) T: 2
anti-infective M: 4
PI regimen
at least two
comedications
Model 3 0.69 (0.64–0.73) 75.2% 58.5% 240 (48.0) 73 (75.3) 114 (78.0) T: 2
WHO stage 3–4 M: 3
PI regimen
at least two
comedications
T, test sample; M, main sample.
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whereas no significant association was found in this cohort.
Higher number of comedications and PI-based regimens are pre-
dictors for DDI risk in this cohort and European settings.3,7 A study
in Argentina found that DDIs affected30% of patients and most
frequently occurred with anti-infectives, CNS drugs and cardiovas-
cular drugs. Age was not associated with increased risk of DDIs,
nor was a PI-containing regimen. Only at least two comedications
and taking a CNS drug were significantly associated with higher
risk of DDIs.8 As prescribing patterns and medication use in
sub-Saharan Africa change, to include more widespread prescrib-
ing of medicines used in chronic conditions and conditions asso-
ciated with advanced age, e.g. CNS and cardiovascular agents, it is
likely that the type of and risk factors for DDIs with ARVs will
change, potentially with some similarities to the data observed
in Argentina and Europe. However, these data suggest the overall
prevalence of potential DDIs is unlikely to decrease, in the absence
of targeted interventions.
Healthcare provision in many resource-limited settings
involves independent silos of healthcare delivery, e.g. vertical
(unintegrated) HIV services, TB treatment and programmes for
treatment of other infectious conditions. This undoubtedly com-
plicates the communication process and increases the risk of
unrecognized DDIs. Taking and recording full drug histories from
patients is therefore important in all healthcare settings. As
patients were not approached to give a full medication history,
and due to the often unintegrated (vertical) nature of treatment
programmes in this setting and potential for widespread use
of over-the-counter (OTC) and traditional herbal medicines,14
these results represent a conservative estimate of the true preva-
lence of DDI in this setting.
In addition, the centre at which the study took place is a large,
relatively well-resourced facility in Kampala, with electronic
patient records and partial electronic prescribing. The results
therefore may not be representative of all centres that provide
HIV services in Uganda, or the rest of sub-Saharan Africa, where
systems and available regimens may differ. Again, this study is
likely to represent a conservative estimate of the true prevalence
of DDIs in ARV programmes in sub-Saharan Africa. Future work will
use an in-depth approach and evaluate the prevalence of DDIs
with full medication lists for each patient, including OTC and
herbal or traditional medicines, and include peripheral, more rep-
resentative centres that provide HIV services.
Using these data, health system interventions will be developed
including prescribing alerts and screening for DDIs in clinic. Such
interventions will be assessed for utility and reduction in patient
harm. For example, in settings where not all patients are routinely
checked for DDIs, due to time, staff or resource constraints, or
where internet access for online DDI resources is limited, a screen-
ing tool can be used to identify patients at high risk. Trained lay
workers, or other healthcare workers involved in patient care,
could be trained to use the screening tool and flag-up high-risk
patients prior to outpatient appointments, so that these patients
can be prioritized for a DDI check. It may be possible to train health-
care workers such as pharmacy technicians to check for DDIs using
a printed chart or, where available, an online database. Another
option would be to put up posters in clinics, displaying the factors
that confer higher risk of DDIs (i.e. WHO stage 3–4, two or more
comedications, use of anti-infectives and a PI-containing ARV regi-
men) and suggesting that patients with two or more of these risk
factors be screened for DDIs.
Potential DDIs involving ARVs occur at similar rates in resource-
limited settings and developed countries, although the comedications
most commonly associated and risk factors differ. Development of
tools, including databases that incorporate drugs in common use
throughout sub-Saharan Africa, is essential for recognition of DDIs.
Understanding risk factors for DDIs in specific settings can allow
patients with known risk factors to be prioritized for DDI screening
in settings with low resources. An understanding of the key DDIs of
clinical relevance in specific settings can allow introduction of inter-
ventions such as alerts on electronic prescribing systems and stand-
ard local guidance for interaction management in settings with
protocol-driven treatment programmes.
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